Compare Mizuho Financial Group Inc. Sponosred ADR (Japan) (MFG) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mizuho Financial Group Inc. Sponosred ADR (Japan) vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Mizuho Financial Group Inc. Sponosred ADR (Japan) trades at $10.46 (market cap $127.85B), while Nuvation Bio Inc. Class A Common Stock trades at $5.22 (market cap $1.74B). The key difference: Mizuho Financial Group Inc. Sponosred ADR (Japan) is far larger — about 73.5× Nuvation Bio Inc. Class A Common Stock's market cap, and Mizuho Financial Group Inc. Sponosred ADR (Japan) pays a 1.72% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mizuho Financial Group Inc. Sponosred ADR (Japan) for 0 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| MFG | NUVB | |
|---|---|---|
Market Cap | $127.85B | $1.74B |
Volume | 3,950,750 | 9,289,619 |
Sector | Financials | Health |
52-Week High | $11.45 | $9.54 |
52-Week Low | $6.09 | $3.41 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $35.14T | $1.33B |
Dividend Yield | 1.72% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Mizuho Financial Group Inc. Sponosred ADR (Japan)
Mizuho Financial Group is a Japanese financial services company offering banking, trust, securities, and asset management services. It serves retail, corporate, and institutional clients globally.
Read more on MFG →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
